Wall Street Zen Downgrades Metsera (NASDAQ:MTSR) to Sell

Key Points

• Investment analysts at Wall Street Zen have downgraded Metsera (NASDAQ:MTSR) from a "hold" rating to a "sell" rating.
• Despite the downgrade, other analysts like Bank of America and Guggenheim have issued "buy" ratings and increased target prices for the stock.
• Metsera, which specializes in biopharmaceuticals for obesity treatment, recently reported a loss of $0.66 earnings per share for the last quarter.

Metsera (NASDAQ:MTSR - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Sunday.

Other equities research analysts have also issued research reports about the stock. Guggenheim upped their price objective on shares of Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a report on Tuesday, June 10th. Wells Fargo & Company assumed coverage on shares of Metsera in a report on Friday, June 20th. They issued an "overweight" rating and a $65.00 price objective for the company. Bank of America upped their price objective on shares of Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a report on Thursday, August 28th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Metsera in a report on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company. Based on data from MarketBeat, Metsera currently has a consensus rating of "Buy" and an average target price of $63.50.

Metsera Price Performance

Shares of NASDAQ MTSR traded down $1.00 during mid-day trading on Friday, reaching $36.25. The company's stock had a trading volume of 272,873 shares, compared to its average volume of 1,032,532. The stock has a 50-day moving average of $35.37 and a two-hundred day moving average of $28.81. Metsera has a 1-year low of $12.30 and a 1-year high of $47.40.

Metsera (NASDAQ:MTSR - Get Free Report) last issued its earnings results on Monday, July 28th. The company reported ($0.66) EPS for the quarter.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of MTSR. Alphabet Inc. purchased a new position in Metsera during the first quarter worth about $135,059,000. T. Rowe Price Investment Management Inc. purchased a new position in Metsera during the first quarter worth about $78,748,000. Wellington Management Group LLP purchased a new position in Metsera during the first quarter worth about $65,382,000. Alpha Wave Global LP purchased a new position in Metsera during the first quarter worth about $64,894,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in Metsera during the first quarter worth about $42,395,000.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.